SGLT-2 Inhibitors and Cardio-renal Outcomes: Translating the Data into Practice

Published: 12 November 2021

  • Views:

    Views Icon 14041
  • Likes:

    Heart Icon 7
  • episode_image
    Now Playing
    Part 2
    Screening for CKD
    Shelley Zieroth, Kamlesh Khunti, Hiddo Lambers Heerspink
    Up Next
Average (ratings)
No ratings
Your rating


Following the release at ESC 2021 of updated guidelines for the diagnosis and treatment of acute and chronic heart failure, Dr Shelley Zieroth (University of Manitoba, CA), Prof Hiddo L Heerspink (University Medical Center, Groningen, NL) and Prof Kamlesh Khunti (University of Leicester, UK) discuss the implications for practice.


This three-part series, 'SGLT-2 Inhibitors and Cardio-renal Outcomes: Translating the Data into Practice', brings together three experts to review the implications for pathophysiology, screening and treatment strategies.


Download infographic ‘SGLT-2 inhibitors and cardio-renal outcomes’

Download Infographic

This programme is supported by an unrestricted educational grant from AstraZeneca

Learning Objectives

  • Recall the existing relationship between chronic kidney disease and cardiovascular disease for patients with and without type 2 diabetes.
  • Consider the global burden of CKD, including for patients with type 2 diabetes, and be aware of existing guidelines for screening.
  • Review treatment options for the treatment of patients with chronic kidney disease, and the role of SGLT2i therapies in available strategies.

Target Audience

  • Cardiologists
  • Endocrinologists
  • Renal specialists

More from this programme

Part 1

Cardio-renal Pathophysiology

Prof Khunti outlines key takeaways of what clinicians need to know about the relationship between chronic kidney disease and cardiovascular disease, and considers whether that differs in patients living with and without type 2 diabetes. Prof Heerspink addresses why clinicians should be encouraged to intervene early for patients living with CKD to attain improved cardiovascular and kidney outcomes.

Part 2

Screening for CKD

Prof Khunti addresses the burden of CKD globally, including the prevalence of CKD in patients with type 2 diabetes. Dr Zieroth asks the faculty about existing tools for screening for CKD, and the recommendations of international guidelines.

Part 3

Treatment Options in CKD

In this final part, moderator Dr Zieroth enquires of the latest treatment options for CKD, with Prof Heerspink advising on evidence supporting the use of treatments, whilst Prof Khunti provides insight to the role of initiating SGLT2 therapy, and underlines the urgency to treat.

Faculty Biographies

Shelley Zieroth

Shelley Zieroth

Director, Heart Failure and Heart Transplant Clinics

Dr Shelley Zieroth is Professor at the College of Medicine, Max Rady Faculty of Health Sciences, University of Manitoba, as well as Director of the Heart Failure and Heart Transplant Clinics at St Boniface Hospital in Winnipeg, Canada. She is also Head of the Medical Heart Failure Program for Cardiac Sciences Manitoba.

She is involved in several heart failure clinical trials as a PI, National Lead or Executive Committee member. She is the Past President of the Canadian Heart Failure Society and Co-Chair of the Canadian Cardiovascular Society Heart Failure Guidelines. She is co-chair of Canada’s largest annual heart failure meeting, HF Update, and Past President of the Federation of Medical Women of Canada.

Dr Shelley Zieroth is an Editorial Board member of Cardiac Failure Review.

View full profile
Kamlesh Khunti

Kamlesh Khunti

Professor of Primary Care Diabetes and Vascular Medicine

Professor Kamlesh Khunti is the Professor of Primary Care Diabetes and Vascular Medicine at the University of Leicester, UK. He is Co-Director of the Leicester Diabetes Centre and leads a research group that is currently working on the early identification of, and interventions with, people who have cardiometabolic disease or are at increased risk of developing cardiometabolic diseases.

His work has influenced national and international guidelines on the screening and management of people with diabetes. Professor Khunti is also Director of the UK National Institute for Health Research (NIHR) in Applied Research Collaborations  (ARC) East Midlands and Director of  The Real World Evidence Unit and Centre for BME Health. He is a NIHR Senior Investigator and Principal Investigator on several major national and international studies. He is the National NIHR ARC Theme Lead for Multimorbidity and Ethnicity and Diversity. He is also Honorary Visiting…

View full profile
Hiddo Heerspink

Hiddo Heerspink

Clinical Pharmacologist

Prof Hiddo Heerspink’s is a Clinical Pharmacologist at the Department of Clinical Pharmacy and Pharmacology at the University Medical Center Groningen, the Netherlands. he also serves as a Visiting Professor at the University of New South Wales in Sydney, Australia. Prof Heerspink's research interests include treatment strategies and therapeutic approaches for the treatment of renal and cardiovascular disease in patients with diabetes.

View full profile